Roivant, the Hedge Fund Specializing in Drug Castoffs, Signs $3 Billion Deal

September 9, 2019 | Hedge Funds
https://dailyalts.com/wp-content/uploads/2019/09/pill-1884777_1920-roivant-sumitomo.jpg

Japanese drugmaker Sumitomo Dainippon Pharma will buy a stake of just over 10% in Roivant Sciences

Roivant Sciences, a Swiss holding company, is the product of former hedge fund manager Vivek Ramaswamy. The firm builds “Vants” – biotech and healthcare companies that license, or own, development drugs sidelined by Big Pharma companies.

Roivant currently owns a central technology-enabled platform and 20 Vants with over 45 investigational medicines under development.

The deal

Sumitomo Dainippon Pharma will acquire Roivant’s ownership interests in five of their biopharmaceutical companies (“Vants”).

These Vants are:

  • Myovant Sciences (women’s health and prostate cancer),
  • Urovant Sciences (urinary diseases),
  • Enzyvant Therapeutics (rare pediatric diseases),
  • Altavant Sciences (rare respiratory diseases),
  • One additional company to be specified

It will also get options to acquire up to 6 additional Vants and access to Roivant’s proprietary technology platforms, DrugOme, and Digital Innovation.

Under the deal, Sumitomo will pay $3 billion upfront to Roivant and takeover a stake of more than 10% of outstanding shares.

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan.

Sumitomo taking a big risk?

Investors in previously listed Vants have taken massive haircuts on their market capitalizations after the companies went public:

  • Urovant Sciences – 25%
  • Myovant Sciences – 50%
  • Axovant Gene Therapies – over 90%

The market has punished the stocks for fear of clinical failures and poor realization on commercialization.

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Shape

Latest Alternative Investment News

https://dailyalts.com/wp-content/uploads/2021/01/office-1.jpg
FinTech: Stilt, The Loan Provider To Immigrants, Raises $100M Debt
January 28, 2021     FinTech, News

Stilt provides loans and financial services to immigrants and people underserved by the banking system. The five-year old startup announced Wednesday its raise of $100 million as a warehouse lending…

https://dailyalts.com/wp-content/uploads/2021/01/chains-433543_640.jpg
Artificial Intelligence: Now AI Can Predict Schizophrenia From Brain Scans
January 28, 2021     Artificial Intelligence, Latest News, News

Researchers at the University of Alberta developed an AI tool for predicting schizophrenia from brain scans of healthy close relatives (such as children or siblings) of persons suffering from the…

https://dailyalts.com/wp-content/uploads/2021/01/bitcoin-2291397_640.jpg
Alternative Investments/Digital: The Wave BTC Income & Growth Fund Clocks 146% Return
January 27, 2021     Alternative Investments, Digital Assets, News

The numbers are out for the Wave BTC Income & Growth Digital Fund’s first full year of trading, and they’re impressive. The fund scored a 145.8% annual gain for its…

https://dailyalts.com/wp-content/uploads/2021/01/container-ship-429951_640.jpg
FinTech: Infinity Maritime Names Four Shipbrokers For Its Alternative Ship Finance Platform

Infinity Maritime aims to provide a sustainable solution for maritime finance by digitizing ship portfolios on its platform. This enables fractional ownership, secondary trading in ships, and the financing of…